This site is intended for health professionals only

At the heart of general practice since 1960

Dementia drugs are worth cost

Your article on NICE's recent guidance on Alzheimer's disease misses the key issue that these drugs have been found to be clinically and cost- effective.

Costs to spiral after NICE Alzheimers decision

Diagnosing and treating people with dementia early enables them to access the support they need to remain independent for longer.

NICE has acknowledged that the treatments significantly delay entry into care. This is an opportunity to boost diagnosis rates, improve people's quality of life and reduce the economic burden. A million people will develop dementia in the next 10 years. We need to recognise the dementia challenge now if we are to ensure people can live well with the condition in the future.

From Professor Clive Ballard
Director of research, Alzheimer's Society

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say